Halozyme Therapeutics Inc. (HALO)
Are You Looking for a Top Momentum Pick? Why Halozyme Therapeutics (HALO) is a Great Choice
Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Halozyme Therapeutics: Running Through 2027
Halozyme Therapeutics shares have appreciated over 80% since my initial coverage and investment in 2024. My previous articles outlined a bullish investment thesis and detailed expectations for HALO's performance in the current year. HALO's stock performance has delivered significant returns, validating the earlier investment case and strategic positioning.
HALO Stock Rises 36% in a Month: Here's What You Should Know
Halozyme stock jumps 36% in a month as strong ENHANZE-driven royalties and recently raised 2026 guidance boost investor confidence.
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why
Halozyme Therapeutics (HALO) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Is Halozyme Therapeutics (HALO) Stock Outpacing Its Medical Peers This Year?
Here is how Halozyme Therapeutics (HALO) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.
Halozyme's Q2 Earnings Beat Estimates, 2026 Outlook Raised, Stock Up
HALO's Q2 earnings and revenues surpass estimates, fueled by higher royalties and product sales. The company raises its 2026 outlook.
Halozyme Therapeutics Q2 Earnings Call Highlights
Halozyme Therapeutics NASDAQ: HALO reported record second-quarter revenue and raised its full-year outlook, citing growth in royalty income from its ENHANZE drug-delivery platform, contributions from newer product launches and revenue from newly signed collaboration agreements.
Halozyme Therapeutics, Inc. (HALO) Q2 2026 Earnings Call Transcript
Halozyme Therapeutics, Inc. (HALO) Q2 2026 Earnings Call Transcript
Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Halozyme Therapeutics (HALO) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates
Halozyme Therapeutics (HALO) came out with quarterly earnings of $2.28 per share, beating the Zacks Consensus Estimate of $1.82 per share. This compares to earnings of $1.54 per share a year ago.
Halozyme: Unique Business Model -- Adds A Powerful Leavening Element To Any Biotech Portfolio
Halozyme (HALO) has delivered ~134% price appreciation since my prior 'Buy' rating in 06/2023. I evaluate whether HALO can sustain its strong growth trajectory or is due for a period of consolidation. The investment thesis centers on HALO's robust royalty revenue and product income as key growth drivers.
Halozyme's Partnerships, Earnings Growth See Shares Near All-Time Highs
Halozyme Therapeutics, Inc. (HALO) shares gain 539% since first Big Money outlier inflow signal in March 2014.
